Base Year
Historical Year
Forecast Year
The global active pharmaceutical ingredient market size was valued at USD 217.22 billion in 2023, driven by the increasing prevalence of diseases across the globe. The market size is anticipated to grow at a CAGR of 5.5% during the forecast period of 2024-2032 to achieve a value of USD 351.71 billion by 2032.
Active pharmaceutical ingredients (API) refers to the biologically active ingredient of a medicine. Generally, a medicine consists of several components, where the primary component is the API. Other additives are typically known as excipients. Often a drug may include many APIs, and its effect on a patient is dependent on the prescription dosage and may differ from person to person. In combination therapy, two or more active drugs are used to treat various symptoms in multiple ways.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
For a range of large and small suppliers, the global active pharmaceutical ingredients (API) market is highly competitive. Companies involved in its production typically specialise in their manufacturing processes and plan their production on the basis of a combination of internal competencies and business possibilities.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Molecule
Market Breakup by Drug Type
Market Breakup by Type of Manufacturer
Market Breakup by Potency
Market Breakup by API Type
Market Breakup by Therapeutic Application
Market Breakup by End User
Market Breakup by Region
The rising proliferation of chronic conditions has led to a rise in drug demand and, thus, to an increase in the global active pharmaceutical ingredients (API) market growth. In addition, some manufacturers are investing in R&D activities in order to offer higher quality, low-cost APIs, which can help cure illnesses outside the reach of small molecular medicinal products. Therefore, pharmaceutical firms move their manufacturing facilities to developing economies and outsource their operations to maximize production and increase input costs. In addition, there is likely to be a substantial increase in the market for generic APIs as a result of a loss of patent rights for blockbuster drugs worth several billion dollars over the next few years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growing number of blockbusters patent expiries is among the key drivers of this industry and provides a substantial chance to generic active pharmaceutical ingredients. In addition, the demand for active pharmaceutical ingredients for bio-based substances has been rising. The global biologics market is currently showing a strong growth, which is catalysed by its high power and ability to treat diseases other than small molecule medicines. This has led to a high demand for APIs and their biosimilar versions of marketed biological drugs. The ageing population, higher expenditure on healthcare, and increased prevalence of lifestyle diseases are the other factors that are catalysing the market development.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Molecule |
|
| Breakup by Drug Type |
|
| Breakup by Type of Manufacturer |
|
| Breakup by Potency |
|
| Breakup by API Type |
|
| Breakup by Therapeutic Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of USD 217.22 billion in 2023, driven by the rising healthcare sector.
The market is expected to grow at a CAGR of about 5.5% during the forecast period of 2024-2032 to reach USD 351.71 billion by 2032.
The growth of the market is driven by factors like rising demand from the emerging nations, growing biologics market, increasing healthcare expenditure, and the rising R&D investments.
The key trend guiding the growth of the market includes the upcoming expiry of blockbuster drugs patents, which provides a significant growth potential for generic active pharmaceutical ingredients.
The major regional markets for the product include North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The major molecules can be categorised into small and large molecule.
The types of the product can be categorised into branded or innovative active pharmaceutical ingredients, generic active pharmaceutical ingredients, and over the counter (OTC) drugs.
The key manufacturers in the market can be divided into captive and merchant API manufacturer.
The potency of the product can be categorised into low to moderate and potent to highly potent.
The product finds wide applications in cardiology, CNS and neurology, oncology, orthopaedic, endocrinology, pulmonology, gastroenterology, nephrology, and ophthalmology, among others.
The end-users of the product include pharmaceutical and biotechnology industry, CROs, and CMOs, among others.
The key players can be categorised into Novartis AG, Sanofi, Pfizer Inc., Johnson & Johnson Private Limited, Abbott, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Jazz Pharmaceuticals, Inc., AstraZeneca, GSK plc, Takeda Pharmaceutical Company Limited, Sumitomo Dainippon Pharma Co., Ltd., and Cadila Pharmaceuticals.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share